Agility in Manufacturing Preparedness Act of 2023 This bill requires the Department of Health and Human Services (HHS) to seek to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals to assess and make recommendations concerning U.S. capabilities for biopharmaceutical manufacturing and related matters. HHS must coordinate with the Biomedical Advanced Research and Development Authority on this contract.
Impact
The legislation seeks to identify gaps in the current biopharmaceutical manufacturing system and draft recommendations for advancing new technologies. By aligning federal capabilities with those available to the private sector, the bill emphasizes the importance of enhancing domestic manufacturing technologies to ensure efficient and effective responses to health emergencies. This initiative is particularly relevant in the context of recent global health challenges, where reliance on foreign supply chains has been scrutinized.
Summary
Senate Bill 36, also known as the Agility in Manufacturing Preparedness Act of 2023, aims to enhance the United States' capacity for biopharmaceutical manufacturing. The bill mandates the Department of Health and Human Services (HHS) to collaborate with the National Institute for Innovation in Manufacturing Biopharmaceuticals to review and assess current domestic manufacturing capabilities. This initiative is part of a broader goal to improve public health and medical readiness in response to potential threats, particularly in biopharmaceutical production.
Contention
While there is general support for improving the country's biopharmaceutical manufacturing capabilities, potential points of contention may arise regarding funding mechanisms and the impact of federal intervention on private sector innovation. Critics may express concerns over the bureaucratic process involved in government contracts and potential delays that could hinder timely advancements in manufacturing technologies. Additionally, stakeholders may debate the balance between regulation and fostering an environment conducive to private sector growth.
American Innovation and Manufacturing Act This bill establishes within the Small Business Administration a credit facility to provide financial assistance to investment companies that finance small manufacturing businesses.
Relative to tenant and contract manufacturers of beer, wine, and liquor; allowing pharmacists to administer influenza, COVID-19, and other FDA licensed vaccines without explicit approval from the general court; and, restricting the purchase of real property on or around military installations.